Conference Coverage EAS 2018 See All Content See past conferences Lisbon, Portugal May 05, 2018 May 08, 2018 News Conference News EAS 2018 Biology in the Back Seat: EAS 2018 Opens With Calls for a Big-Picture Approach to CVD Prevention Given the known economic and social issues, experts agree that prevention efforts on a global scale need to take a wider view than lipid-lowering drugs. News Conference News EAS 2018 EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms Yael L. Maxwell May 11, 2018 News Conference News EAS 2018 Unlocking Lp(a): Baseline Levels Matter, but So Too Does Absolute Reduction Yael L. Maxwell May 08, 2018 Presentation EAS 2018 Stress, Behavior and Cardiovascular Disease Presenter: Viola Vaccarino May 06, 2018 Presentation EAS 2018 LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis Presenter: Brian A. Ference May 07, 2018 Presentation EAS 2018 Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial Presenter: Michelle L. O’Donoghue May 07, 2018 @TCTMD Follow Us
News Conference News EAS 2018 Biology in the Back Seat: EAS 2018 Opens With Calls for a Big-Picture Approach to CVD Prevention Given the known economic and social issues, experts agree that prevention efforts on a global scale need to take a wider view than lipid-lowering drugs.
News Conference News EAS 2018 EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms Yael L. Maxwell May 11, 2018
News Conference News EAS 2018 Unlocking Lp(a): Baseline Levels Matter, but So Too Does Absolute Reduction Yael L. Maxwell May 08, 2018
Presentation EAS 2018 Stress, Behavior and Cardiovascular Disease Presenter: Viola Vaccarino May 06, 2018
Presentation EAS 2018 LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis Presenter: Brian A. Ference May 07, 2018
Presentation EAS 2018 Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial Presenter: Michelle L. O’Donoghue May 07, 2018